Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Emmaus Life Sciences's free cash flow for the twelve months ending Dec 31, 2025 was -$12.00K. For fiscal 2025 it was -$12.00K. The highest annual figure on record is -$12.00K in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.00K | – |
| FY2024 | Dec 31, 2024 | -$2.30M | – |
| FY2023 | Dec 31, 2023 | -$1.52M | – |
| FY2022 | Dec 31, 2022 | -$5.10M | – |
| FY2021 | Dec 31, 2021 | -$1.33M | – |
| FY2020 | Dec 31, 2020 | -$2.47M | – |
| FY2019 | Dec 31, 2019 | -$4.58M | – |
| FY2017 | Sep 30, 2017 | -$4.92M | – |
| FY2016 | Sep 30, 2016 | -$2.98M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $2.21M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $409.00K | +200.7% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $337.00K | -67.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $149.00K | +156.9% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$2.92M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $136.00K | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.03M | -38.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $58.00K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.31M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.30M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $1.67M | +107.8% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$954.00K | -158.5% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$1.08M | -156.5% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$4.74M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $803.00K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $1.63M | -9.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $1.91M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$2.64M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$3.54M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $1.81M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$3.30M | – |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | -$86.00K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.16M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$1.07M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$918.50K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$767.40K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$949.70K | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$691.80K | – |
See a number that looks wrong?